ArthemiR CT-ATX-01-DM1-1.1

A phase 1/2a, double-blind, placebo-controlled, single-ascending-dose and multiple-ascending-dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of intravenous ATX-01 in participants aged 18 to 64 years with myotonic dystrophy type 1.